FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

SOLARA Share Price Discussion

Solara Active Pharma Sciences Ltd.
Sector: Pharmaceuticals and health care
... Read more
SOLARA Long Term Analysts Rating
0/5 (0 Ratings)
SOLARA Share Price *
428 -1.15 (-0.27%)
* (quote may be delayed)

Find answers to all your questions on live SOLARA message board: Is SOLARA buy or sell? Should I buy SOLARA shares? Why are SOLARA shares falling? Should I invest in SOLARA stock?


SOLARA Discussion Forum

@invictotrader • Reputation: 2,053

Solara Active Pharma share price rises 3% on merger nod SCPL and the company are both engaged in the manufacture and sale of active pharmaceutical ingredients for the pharmaceutical industry.
Like
reply
Reply
@ravikanthchopperla • Reputation: 10,669

NCLT sanctions scheme of merger between Strides Chemicals & Solara Active Pharma
Like
reply
Reply
@newsbot • Reputation: 1,933
Solara Active Q2 serves a strong dose, new molecules key trigger
Moneycontrol
Like
reply
Reply
@umanath • Reputation: 563

SOLARA - 408869

Like
reply
Reply
@newsbot • Reputation: 1,933
Ranitidine controversy: Which Indian pharma companies stand to lose?
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,933
Exclusive | TPG Capital still in hunt to buy hospitals in India after Medanta deal fell through
The private equity firm plans to invest $500 million-$1 billion yearly
Moneycontrol
Like
reply
Reply
@guptan • Reputation: 2,839

SOLARA - chart - 360816
Solara
Like
reply
Reply
@newsbot • Reputation: 1,933
This pure API play gains strength on improving product mix
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
@newsbot • Reputation: 1,933
Like
reply
Reply
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.